Jon Edward Chatterton

US Patent:

20220370357, Nov 24, 2022

Filed:

Nov 23, 2020

Appl. No.:

17/642314

Inventors:

- Cambridge MA, US
Birte Nolting - Cambridge MA, US
Gregory Feinstein - Cambridge MA, US
Michelle LeBlanc - Cambridge MA, US
Jon Edward Chatterton - Cambridge MA, US

International Classification:

A61K 9/16
C07C 323/26
C07C 323/27
C07D 211/24
C07D 207/08
A61K 48/00
A61K 31/573

Abstract:

Provided herein are ionizable lipids represented by the Formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, m, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising an ionizable lipid of the invention and a capsid-free, non-viral vector (e.g., ceDNA). These LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

US Patent:

20220280427, Sep 8, 2022

Filed:

Sep 3, 2020

Appl. No.:

17/632262

Inventors:

- Cambridge MA, US
Prudence Yui Tung Li - Cambridge MA, US
Debra Klatte - Cambridge MA, US
Leah Yu Liu - Cambridge MA, US
Matthew James Chiocco - Cambridge MA, US
Matthew G. Stanton - Cambridge MA, US
Jeff Moffit - Cambridge MA, US
Jon Edward Chatterton - Cambridge MA, US

International Classification:

A61K 9/127
A61K 48/00
A61K 31/573

Abstract:

Provided herein are lipid formulations comprising a lipid and a capsid free, non-viral vector (e.g. ceDNA). Lipid particles (e.g., lipid nanoparticles) of the invention include a lipid formulation that can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

US Patent:

20220204929, Jun 30, 2022

Filed:

Mar 14, 2022

Appl. No.:

17/694210

Inventors:

- Durham NC, US
Jon E. Chatterton - Needham MA, US
Michelle Brenda Pires - Apex NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783
C12N 15/11
C12N 15/113

Abstract:

The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.

US Patent:

20210254002, Aug 19, 2021

Filed:

Apr 8, 2021

Appl. No.:

17/225788

Inventors:

- Durham NC, US
Jon E. Chatterton - Needham MA, US
Michelle Brenda Pires - Apex NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783
C12N 15/11

Abstract:

The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.

US Patent:

20200370014, Nov 26, 2020

Filed:

Jun 22, 2020

Appl. No.:

16/908030

Inventors:

- Durham NC, US
Jon E. Chatterton - Needham MA, US
Michelle Brenda Pires - Apex NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783

Abstract:

The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.

US Patent:

20190032061, Jan 31, 2019

Filed:

Oct 11, 2018

Appl. No.:

16/157726

Inventors:

- Pasadena CA, US
Jon E. Chatterton - Aliso Viejo CA, US
Diane Michelle Senchyna - Corona del Mar CA, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US

International Classification:

C12N 15/113
A61K 31/713
A61K 31/7088

Abstract:

RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

US Patent:

20170073681, Mar 16, 2017

Filed:

Nov 30, 2016

Appl. No.:

15/364992

Inventors:

- Pasadena CA, US
Wan-Heng Wang - Foth Worth TX, US
Loretta Graves McNatt - Hurst TX, US
Jon E. Chatterton - Aliso Viejo CA, US

International Classification:

C12N 15/113
A61K 31/713

Abstract:

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

US Patent:

20170056507, Mar 2, 2017

Filed:

Nov 16, 2016

Appl. No.:

15/352754

Inventors:

- Pasadena CA, US
Jon E. Chatterton - Aliso Viejo CA, US

International Classification:

A61K 47/48
C12N 15/113
C07K 16/28

Abstract:

The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.